Key facts
- Adaptyx’s last known valuation is $41.0M (Oct 2025).
- It has raised $19.0M; the latest was Early Stage VC ($14.0M) in Oct 2025.
- Notable investors include MedTech Innovator, Stanford University, Humba Ventures, Hyperlink Ventures, Starbloom Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Adaptyx
- ·The full record, as it builds
Funding rounds
No funding rounds for Adaptyx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adaptyx
Developer of microneedle sensor patch designed to monitor blood. The company's devices use aptamer-based molecular switching that is used to simultaneously detect multiple metabolic health markers, enabling customers to monitor and detect any abnormalities in the body.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2022
- Employees
- 10
- Website
- adaptyx.bio/
- Ownership
- Privately Held (backing)
Adaptyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adaptyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adaptyx in its N-PORT filings yet. We sweep new filings monthly.